VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
| Recruiting | N/A | 1200 | Europe | UDCA, ursodeoxycholic acid, Ocaliva, obeticholic acid | University of Leipzig, RWTH Aachen University, Zentrum für Klinische Studien Leipzig, Intercept Pharma Europe Limited (IPEL), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University Hospital Erlangen, Medical care center for Gastroenterology, Berlin, Institute for Interdisciplinary Medicine, Hamburg, Leberhilfe Projekt gUG, Cologne, Hannover Medical School | PBC, Primary Biliary Cholangitis | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | Europe | polyreactive immunoglobulin G, Conventional diagnostic autoantibodies | Hannover Medical School | Autoimmune Hepatitis, Autoimmune Liver Disease | 07/26 | 01/27 | | |
